Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore?

Key PointsNovo Nordisk was first to market with a GLP-1 weight-loss drug, but lost the lead to Eli Lilly.

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Read the original at nasdaq.com →

More in Finance & Markets

More from Tuesday 8 September →